Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Mar 30, 2022 1:41pm
70 Views
Post# 34559728

Organ Scoring = SQI Diagnostics = Massive

Organ Scoring = SQI Diagnostics = Massive Chest CT of Lung Injury 1 Year after #COVID19 Pneumonia

The researchers assessed lung abnormalities on chest CT in 91 participants, mean age 59 years, at several points over one year after the onset of COVID-19 symptoms.

At one year, CT abnormalities were present in 49, or 54%, of the 91 participants. 

Of these 49 participants, two (4%) had received outpatient treatment only, while 25 (51%) were treated on a general hospital ward and 22 (45%) had received intensive care unit (ICU) treatment.

While CT abnormalities decreased in initial follow-ups, 63% of participants with abnormalities did not show any further improvement after six months. 

Age over 60 years, critical COVID-19 severity and male gender were associated with persistent CT abnormalities at one year.

https://pubs.rsna.org/doi/abs/10.1148/radiol.211670
<< Previous
Bullboard Posts
Next >>